Stefan Stender

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7315295/publications.pdf

Version: 2024-02-01

40 papers	4,089 citations	279798 23 h-index	330143 37 g-index
42 all docs	42 docs citations	42 times ranked	6764 citing authors

#	Article	IF	Citations
1	Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2014, 46, 352-356.	21.4	938
2	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	13.7	562
3	A Protein-TruncatingHSD17B13Variant and Protection from Chronic Liver Disease. New England Journal of Medicine, 2018, 378, 1096-1106.	27.0	556
4	Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nature Genetics, 2017, 49, 842-847.	21.4	288
5	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. Journal of Internal Medicine, 2018, 283, 356-370.	6.0	256
6	Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279â€‰013 individuals. European Heart Journal, 2018, 39, 385-393.	2.2	152
7	Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2011, 103, 508-519.	6.3	134
8	Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology, 2020, 72, 845-856.	7.3	132
9	Elevated body mass index as a causal risk factor for symptomatic gallstone disease: A Mendelian randomization study. Hepatology, 2013, 58, 2133-2141.	7.3	101
10	Genetically elevated bilirubin and risk of ischaemic heart disease: three <scp>M</scp>endelian randomization studies and a metaâ€analysis. Journal of Internal Medicine, 2013, 273, 59-68.	6.0	84
11	Adeno-associated viral vector transduction of human mesenchymal stem cells. , 2007, 13, 93-99.		82
12	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	3.7	77
13	Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies. Gastroenterology, 2016, 151, 351-363.e28.	1.3	74
14	High Risk of Fatty Liver Disease Amplifies the Alanine Transaminaseâ€“Lowering Effect of a HSD17B13 Variant. Hepatology, 2020, 71, 56-66.	7.3	60
15	Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. European Heart Journal, 2015, 36, 1601-1608.	2.2	59
16	Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride. Hepatology, 2018, 67, 2182-2195.	7.3	51
17	Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population. Hepatology, 2011, 53, 640-648.	7.3	48
18	The ABCG5/8 Cholesterol Transporter and Myocardial Infarction Versus Gallstone Disease. Journal of the American College of Cardiology, 2014, 63, 2121-2128.	2.8	45

#	Article	IF	Citations
19	Extreme Bilirubin Levels as a Causal Risk Factor for Symptomatic Gallstone Disease. JAMA Internal Medicine, 2013, 173, 1222.	5.1	42
20	HSD17B13 and Chronic Liver Disease in Blacks and Hispanics. New England Journal of Medicine, 2018, 379, 1876-1877.	27.0	39
21	Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis. Clinical Gastroenterology and Hepatology, 2022, 20, 1784-1794.e9.	4.4	38
22	Adult-onset liver disease and hepatocellular carcinoma in S-adenosylhomocysteine hydrolase deficiency. Molecular Genetics and Metabolism, 2015, 116, 269-274.	1.1	37
23	APOC3, Coronary Disease, and Complexities of Mendelian Randomization. Cell Metabolism, 2014, 20, 387-389.	16.2	34
24	The Effect of Overweight and Obesity on Liver Biochemical Markers in Children and Adolescents. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 430-442.	3.6	34
25	PNPLA3 Genotype and Risk of Liver and Allâ€Cause Mortality. Hepatology, 2020, 71, 777-779.	7.3	23
26	Low-density lipoprotein cholesterol and risk of gallstone disease: A Mendelian randomization study and meta-analyses. Journal of Hepatology, 2013, 58, 126-133.	3.7	22
27	Use of Allele-Specific FAIRE to Determine Functional Regulatory Polymorphism Using Large-Scale Genotyping Arrays. PLoS Genetics, 2012, 8, e1002908.	3.5	21
28	Identification and Replication of Six Loci Associated With Gallstone Disease. Hepatology, 2019, 70, 597-609.	7.3	18
29	Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. Journal of Infectious Diseases, 2020, 222, 1353-1362.	4.0	17
30	Assessment of Rapid Hepatic Glycogen Synthesis in Humans Using Dynamic 13C Magnetic Resonance Spectroscopy. Hepatology Communications, 2020, 4, 425-433.	4.3	12
31	Using human genetics to predict the effects and side-effects of drugs. Current Opinion in Lipidology, 2016, 27, 105-111.	2.7	10
32	Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. International Journal of Epidemiology, 2017, 46, 1777-1785.	1.9	10
33	HSD17B13 as a promising therapeutic target against chronic liver disease. Liver International, 2020, 40, 756-757.	3.9	9
34	Genetic Variation in Liver X Receptor Alpha and Risk of Ischemic Vascular Disease in the General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2990-2996.	2.4	7
35	Genetic Variation atPPP1R3BIncreases Hepatic CT Attenuation and Interacts With Prandial Status on Plasma Glucose. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1963-1972.	3.6	6
36	A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population. Hepatology International, 2022, 16, 702-711.	4.2	4

#	Article	IF	Citations
37	Genetic Variation in NPC1L1 and Risk of Gallstone Disease. Journal of the American College of Cardiology, 2015, 66, 1086.	2.8	2
38	Response to: liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease. European Heart Journal, 2018, 39, 3399-3399.	2.2	1
39	Genetic Aspects of Non-alcoholic Fatty Liver Disease (NAFLD). , 2019, , 195-206.		1
40	Metabolic and genetic risk factors predict advanced alcohol-related liver fibrosis regardless of drinking pattern. Journal of Hepatology, 2020, 73, S186-S187.	3.7	0